Nox Health Closes Acquisition of Somryst, the Only FDA-Cleared Digital Insomnia Treatment, From Pear TherapeuticsGlobeNewsWire • 06/20/23
Pear Therapeutics Files for Chapter 11 and Will Seek to Sell Assets Through Sales ProcessBusiness Wire • 04/07/23
Pear Therapeutics to Participate in the 2023 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceBusiness Wire • 02/02/23
Pear Therapeutics and BrightView Health Expand Pilot Program to Provide Prescription Digital Therapeutics for the Treatment of Substance Use DisordersBusiness Wire • 01/26/23
Pear Therapeutics, Inc. (PEAR) Loses -17.39% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 01/19/23
Pear Therapeutics Announces Inclusion of reSET® and reSET-O® on the January 2023 Florida Medicaid Preferred Drug ListBusiness Wire • 01/18/23
Pear Therapeutics to Participate in Citi's BioTech C-Suite Virtual Fireside Chat SeriesBusiness Wire • 01/17/23
California Department of Health Care Services Awards Contract to Pear Therapeutics to Support the Recovery Incentives ProgramBusiness Wire • 01/12/23
Pear Therapeutics and COEUS Healthcare Partner to Combat the Addiction Crisis With Prescription Digital TherapeuticsBusiness Wire • 01/10/23
Pear Therapeutics and Spero Health to Expand Access to Prescription Digital Therapeutics for People in Recovery Across Multiple Locations and StatesBusiness Wire • 01/04/23
Pear Therapeutics Presents Real-World Clinical Data Assessing Engagement and Abstinence in Patients with Alcohol Use Disorders Using reSET® at AAAPBusiness Wire • 12/15/22
Pear Therapeutics to Participate in Evercore ISI 5th Annual HealthCONx ConferenceBusiness Wire • 11/21/22
Pear Therapeutics Presents Real-World Data Showing Reduction in Healthcare Resource Utilization and Associated Costs in Adults Using Somryst® at ISPOR EuropeBusiness Wire • 11/07/22
State of Wisconsin to Provide Access to Prescription Digital Therapeutics to Help Local Communities Fight Against Addiction CrisisBusiness Wire • 11/03/22
Pear Therapeutics to Participate in the Credit Suisse 31st Annual Healthcare ConferenceBusiness Wire • 11/01/22
Pear Therapeutics to Issue Third Quarter 2022 Financial Results on Monday, November 14, 2022Business Wire • 10/31/22
Pear Therapeutics Announces Publication of Real-World Data Showing High Rates of Engagement, Retention and Abstinence with reSET®Business Wire • 10/24/22